(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
Live Chart Being Loaded With Signals
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis...
Stats | |
---|---|
本日の出来高 | 3 777.00 |
平均出来高 | 68 195.00 |
時価総額 | 65.60M |
EPS | $0 ( 2024-03-11 ) |
次の収益日 | ( $0 ) 2024-05-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.78 |
ATR14 | $0 (0.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-13 | Phillips Anne M. | Buy | 0 | |
2024-03-05 | Baker Bros. Advisors Lp | Buy | 52 925 | Prefunded Warrants |
2024-03-05 | Baker Bros. Advisors Lp | Buy | 4 780 | Prefunded Warrants |
2024-03-05 | Baker Bros. Advisors Lp | Sell | 52 881 | Common Stock |
2024-03-05 | Baker Bros. Advisors Lp | Sell | 4 776 | Common Stock |
INSIDER POWER |
---|
59.88 |
Last 83 transactions |
Buy: 13 416 272 | Sell: 2 785 487 |
vTv Therapeutics Inc 相関
10 最も正の相関 | |
---|---|
SIFY | 0.816 |
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
vTv Therapeutics Inc 財務諸表
Annual | 2023 |
収益: | $0 |
総利益: | $-90 000.00 (0.00 %) |
EPS: | $-9.71 |
FY | 2023 |
収益: | $0 |
総利益: | $-90 000.00 (0.00 %) |
EPS: | $-9.71 |
FY | 2022 |
収益: | $2.02M |
総利益: | $1.93M (95.44 %) |
EPS: | $-13.39 |
FY | 2021 |
収益: | $4 005.00 |
総利益: | $4 005.00 (100.00 %) |
EPS: | $-0.000276 |
Financial Reports:
No articles found.
vTv Therapeutics Inc
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator for renal diseases through partnerships with pharmaceutical partners. The company has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。